CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i> -Deleted Cancer

Combining PRMT5 and MAPK pathway inhibitors leads to complete, durable responses in lung cancer models, providing an effective therapeutic strategy for the 4-5% of cancer patients harboring CDKN2A/MTAP deletion and MAPK alterations. See related article by Drizyte-Miller et al., p. 3540.